Mice with Spontaneous Mammary Tumors Develop Type-Specific Neutralizing and Cytotoxic Antibodies Against the Mouse Mammary Tumor Virus Envelope Protein gp52

Sera from C3H mammary tumor-bearing mice contain cytotoxic antibodies for mouse mammary tumor virus (MMTV)-producing cells, based on 51Cr release in a complement-dependent serum cytotoxicity assay. The cytotoxic antibodies could be absorbed by purified C3H MMTV gp52 and C3H MMTV-infected cat cells (C3H [MMTV] CrFK) containing cell surface MMTV gp52. However, purified MMTV p27 and uninfected CrFK cat cells were negative. Absorption of the sera with GR (MMTV) CrFK cells also removed all of the cytotoxicity, whereas absorption with RIII (MMTV) CrFK cells was negative, even though all three infected cat cells contained equivalent amounts of gp52. The same C3H cytotoxic sera also neutralized the focus-forming capacity of a C3H MMTV pseudotype of Kirsten sarcoma virus containing MMTV gp52. In contrast, sera from mammary tumor-bearing GR and RIII mice did not neutralize the pseudotype. Furthermore, neutralization could be achieved only by anti-gp52 but not by anti-gp36, -p27, -p14, or -p10 C3H MMTV sera. The gp52's of C3H, GR, and RIII MMTV could also be distinguished by using a type-specific competition radioimmunoassay employing 125I-gp52 of C3H MMTV and a hyperimmune rabbit anti-C3H MMTV serum. To demonstrate these differences directly, we studied the primary structure of gp52 on the surface of the C3H, GR, and RIII (MMTV) CrFK cells. Two-dimensional tryptic peptide maps of the cell surface lactoper-oxidase-catalyzed iodinated gp52's revealed a greater number of peptides common to the gp52's of C3H and GR MMTVs than to RIII MMTV gp52. These results demonstrate that gp52 is a major target antigen for both cytotoxic and neutralizing antibodies, that the cell surface and virion-associated gp52's of C3H, GR, and RIII MMTV contain both group- and type-specific determinants, and that C3H and GR MMTV gp52's are antigenically more related to each other than to RIII MMTV gp52. Furthermore, C3H mammary tumor-bearing mice develop type-specific antibodies capable of recognizing unique gp52 determinants and, therefore, are able to distinguish the gp52 of C3H MMTV from the gp52's of GR and RIII MMTV.

[1]  G. Schochetman,et al.  Generation of a mouse mammary tumor virus (MMTV) pseudotype of Kirsten sarcoma virus and restriction of MMTV gag expression in heterologous infected cells. , 1979, Virology.

[2]  L. Arthur,et al.  Immunological characterization of mouse mammary tumor virus p10 and its presence in mammary tumors and sera of tumor-bearing mice , 1979, Journal of virology.

[3]  L. Arthur,et al.  Naturally occurring humoral immunity to murine mammary tumor virus (MuMTV) and MuMTV GP52 in mice with low mammary tumor incidence , 1978, International journal of cancer.

[4]  R. Compans,et al.  Structural components of mouse mammary tumor virus. III. Composition and tryptic peptides of virion polypeptides. , 1978, Virology.

[5]  R. Lerner,et al.  Strain-specific markers for the major structural proteins of highly oncogenic murine mammary tumor viruses by tryptic peptide analyses , 1978, Journal of virology.

[6]  L. Arthur,et al.  Coexistence of the mouse mammary tumor virus (MMTV) major glycoprotein and natural antibodies to MMTV in sera of mammary tumor-bearing mice. , 1978, Virology.

[7]  L. Arthur,et al.  Isolation of separate precursor polypeptides for the mouse mammary tumor virus glycoproteins and nonglycoproteins. , 1978, Virology.

[8]  M. Boiocchi,et al.  Polymorphism in the major core protein (p30) of murine leukemia viruses as identified by mouse antisera. , 1978, Virology.

[9]  L. Arthur,et al.  Gene order of the mouse mammary tumor virus glycoproteins. , 1977, Virology.

[10]  J. Schlom,et al.  Type-specific antigenic determinants on the major external glycoprotein of high- and low-oncogenic murine mammary tumor viruses , 1977, Journal of virology.

[11]  J. Schlom,et al.  Characterization of mouse mammary tumor viruses propagated in heterologous cells. , 1977, Cancer research.

[12]  H. Varmus,et al.  Comparison of mouse mammary tumor virus-specific DNA in inbred, wild and Asian mice, and in tumors and normal organs from inbred mice. , 1977, Journal of molecular biology.

[13]  L. Arthur,et al.  Autogenous immunity to mouse mammary tumor virus in mouse strains of high and low mammary tumor incidence. , 1976, Cancer research.

[14]  J. Ihle,et al.  Characterization of the type and group specificities of the immune response in mice to murine leukemia viruses , 1976, Journal of virology.

[15]  I. Weissman,et al.  Oncornavirus budding: kinetics of formation and utilization of viral membrane glycoprotein. , 1976, Virology.

[16]  S W Kessler,et al.  Rapid isolation of antigens from cells with a staphylococcal protein A-antibody adsorbent: parameters of the interaction of antibody-antigen complexes with protein A. , 1975, Journal of immunology.

[17]  L. Arthur,et al.  In vitro system for production of mouse mammary tumor virus. , 1974, Applied microbiology.

[18]  J. August,et al.  Structural Proteins of Mammalian Oncogenic RNA Viruses: Multiple Antigenic Determinants of the Major Internal Protein and Envelope Glycoprotein , 1974, Journal of virology.

[19]  A. Hackett,et al.  Tissue culture studies of mouse mammary tumor cells and associated viruses. , 1972, Journal of the National Cancer Institute.

[20]  R. Massey,et al.  Lymphocyte and antibody cytotoxicity to tumor cells measured by a micro- 51 chromium release assay. , 1972, Immunological communications.

[21]  J. Staats Standardized nomenclature for inbred strains of mice: fifth listing. , 1972, Cancer research.

[22]  P. Bentvelzen,et al.  Hereditary infections with mammary tumor viruses in mice. , 1969, Journal of the National Cancer Institute.